What is Epsilogen?
Epsilogen is at the forefront of developing pan-isotype antibody therapeutics, targeting challenging cancers with a unique focus on immunoglobulin IgE, IgA, and IgG-based therapies. Their lead candidate, MOv18 IgE, represents a first-in-class therapeutic IgE antibody currently in clinical trials for platinum-resistant ovarian cancer. By strategically matching antibody isotypes to specific cancer types and exploring combination therapies, Epsilogen aims to enhance anti-cancer efficacy and optimize immune responses, positioning itself as a key innovator in the oncology landscape.
How much funding has Epsilogen raised?
Epsilogen has raised a total of $67.8M across 3 funding rounds:
Series A
$6.3M
Other Financing Round
$3.9M
Series B
$57.6M
Series A (2017): $6.3M with participation from Epidarex Capital, Alsa Holdings, and UCL Technology Fund
Other Financing Round (2020): $3.9M led by Epidarex Capital, Alsa Holdings, and UCL Technology Fund
Series B (2024): $57.6M supported by Epidarex Capital, Schroders Capital, Caribou Property Management, British Patient Capital, 3B Future Health Fund, ALSA Ventures, and Novartis Venture Fund
Key Investors in Epsilogen
Epidarex Capital
Epidarex Capital is a venture capital firm specializing in building life science companies, acting as a trusted partner to founders and co-investors with a focus on emerging hubs and innovative biopharmaceutical developments.
UCL Technology Fund
The UCL Technology Fund invests in commercializing research from University College London, providing capital and expertise to scale ventures globally, with a focus on physical and life sciences innovations.
Schroders Capital
Schroders Capital is an investment management firm that provides a range of private market solutions, including private equity, private debt, and real estate, aiming to deliver attractive risk-adjusted returns for its clients.
What's next for Epsilogen?
The substantial Series B financing, coupled with previous investment rounds, signals a critical growth phase for Epsilogen. This capital infusion is expected to accelerate the clinical development of MOv18 IgE and potentially expand the company's pipeline of antibody-based cancer therapies. The strategic nature of the recent investment suggests a focus on advancing towards commercialization and solidifying market position in the competitive biopharmaceutical sector. Epsilogen's trajectory indicates a strong commitment to translating cutting-edge research into impactful treatments for patients with unmet medical needs.
See full Epsilogen company page
